Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report)'s share price was up 8.4% during trading on Tuesday following insider buying activity. The company traded as high as $4.70 and last traded at $4.77. Approximately 437,729 shares were traded during mid-day trading, a decline of 78% from the average daily volume of 1,978,886 shares. The stock had previously closed at $4.40.
Specifically, insider Kevin Mcculloch acquired 25,000 shares of the firm's stock in a transaction dated Friday, June 13th. The stock was acquired at an average cost of $4.38 per share, with a total value of $109,500.00. Following the transaction, the insider now owns 1,708,585 shares in the company, valued at approximately $7,483,602.30. This trade represents a 1.48% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Analyst Ratings Changes
A number of analysts have weighed in on the company. Leerink Partners raised their price target on Xeris Biopharma from $5.00 to $6.00 and gave the company an "outperform" rating in a research note on Friday, March 7th. Craig Hallum raised their target price on Xeris Biopharma from $5.00 to $6.50 and gave the stock a "buy" rating in a research report on Friday, March 7th. Wall Street Zen cut Xeris Biopharma from a "buy" rating to a "hold" rating in a research note on Thursday, May 22nd. Oppenheimer increased their price target on shares of Xeris Biopharma from $6.00 to $7.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Finally, HC Wainwright reissued a "buy" rating and set a $8.00 price objective (up previously from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Xeris Biopharma presently has an average rating of "Moderate Buy" and a consensus price target of $6.25.
Read Our Latest Research Report on XERS
Xeris Biopharma Price Performance
The firm has a market cap of $705.27 million, a price-to-earnings ratio of -15.03 and a beta of 0.71. The stock has a 50-day moving average price of $4.57 and a 200 day moving average price of $4.15.
Xeris Biopharma (NASDAQ:XERS - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The firm had revenue of $57.80 million for the quarter, compared to analysts' expectations of $57.61 million. As a group, equities research analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.
Hedge Funds Weigh In On Xeris Biopharma
A number of hedge funds have recently modified their holdings of the business. Nuveen LLC acquired a new stake in Xeris Biopharma during the 1st quarter worth $12,240,000. Parkman Healthcare Partners LLC increased its stake in Xeris Biopharma by 207.8% in the first quarter. Parkman Healthcare Partners LLC now owns 1,780,454 shares of the company's stock valued at $9,775,000 after purchasing an additional 1,201,943 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of Xeris Biopharma by 75.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company's stock valued at $15,317,000 after buying an additional 1,199,435 shares during the last quarter. Invesco Ltd. boosted its stake in shares of Xeris Biopharma by 1,387.8% during the first quarter. Invesco Ltd. now owns 1,026,838 shares of the company's stock worth $5,637,000 after buying an additional 957,822 shares during the period. Finally, Driehaus Capital Management LLC boosted its stake in shares of Xeris Biopharma by 137.6% during the first quarter. Driehaus Capital Management LLC now owns 1,411,540 shares of the company's stock worth $7,749,000 after buying an additional 817,525 shares during the period. 42.75% of the stock is currently owned by hedge funds and other institutional investors.
About Xeris Biopharma
(
Get Free Report)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Read More
Before you consider Xeris Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xeris Biopharma wasn't on the list.
While Xeris Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
